Agar dilution was used to determine the MICs of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents for 203 penicillin-susceptible and -resistant pneumococci. All pneumococci were inhibited by RPR 106972 at <0.5 g/ml. Cefditoren was very active against all pneumococcal groups, with MICs of <2.0 g/ml. Amoxicillin with or without clavulanate was the next most active oral ␤-lactam, followed by cefdinir, cefuroxime, cefpodoxime, and cefprozil. U-100592 and U-100766 were very active against all classes of pneumococci, with all MICs <1.0 g/ml.
The worldwide incidence of infections caused by pneumococci resistant to penicillin G and other antimicrobial agents has increased at an alarming rate during the past two decades and in particular the past 5 years (1). The main foci of penicillin-resistant pneumococci are currently South Africa, Spain, Eastern Europe, and Korea. In the United States, recent surveys (5) have shown an increase in resistance to penicillin from Ͻ5% before 1989 (with MICs of Ն2.0 g/ml for Ͻ0.02% of isolates) to 6.6% in 1991 to 1992 (with MICs of Ն2.0 g/ml for 1.3% of isolates).
The distribution of resistant strains in the United States is highly variable. Block and coworkers (4) have recently reported a 28% incidence of penicillin-resistant pneumococci from middle-ear fluids of children with acute otitis media in Kentucky and a 29% incidence of these strains in nasopharyngeal cultures from children with otitis media in Tennessee.
There is an urgent need for an oral antimicrobial agent which can be used for infections such as pneumonia, bronchitis, sinusitis, and otitis media and a parenteral compound active against bacteremia and meningitis caused by penicillinresistant pneumococci (11, 13) . RPR 106972 (a combination of RPR 112808 and RPR 106950), a new oral streptogramin (3) (Fig. 1) , is chemically related to RP 59500 (quinupristin-dalfopristin), and preliminary studies show that it is similarly active against pneumococci (3, 20, 24) .
Previous studies have documented relatively high MICs for all groups of oral cephalosporins tested against penicillin-resistant pneumococci, with cefdinir, cefuroxime, and cefpodoxime having the lowest MICs for the group, followed by cefprozil and cefaclor or cefixime (2, 14, 15, 19, 25, 26) . The MICs of amoxicillin are lower than those of penicillin G, ampicillin, and oral cephalosporins against these strains (10, 21, 25) . Cefditoren, a new oral cephalosporin in pivaloyloxymethyl ester form (16) (Fig. 2) , has previously been shown to have the lowest MICs of all ␤-lactams against penicillin-susceptible as well as penicillin-resistant pneumococci (7, 9, 18) .
The oxazolidinones (Fig. 3 ) are a new class of compounds active against gram-positive aerobic cocci (6, 23) . The current study examined the activities of two oxazolidinones (U-100592 and U-100766), RPR 106972 and its constituent components RPR 112808 and RPR 106950, cefditoren, amoxicillin, amoxicillin-clavulanate, cefdinir, cefpodoxime, cefuroxime, cefaclor, cefixime, cefprozil, ceftriaxone, erythromycin, ciprofloxacin, sparfloxacin, rifampin, imipenem, teicoplanin, and vancomycin against 203 penicillin-susceptible and -resistant pneumococci.
A total of 203 isolates of Streptococcus pneumoniae from blood, cerebrospinal fluid, ear fluid, nasopharynx, or sputum samples were examined. Seventy-five strains susceptible to penicillin (MIC, Ͻ0.1 g/ml) were isolated from various hospitals in the United States. Seventy-three isolates resistant to penicillin (MIC, Ն2.0 g/ml) and most of the 55 strains intermediately resistant to penicillin (MIC, 0.1 to 1.0 g/ml) were isolated in the United States, South Africa, France, Spain, Eastern Europe (Hungary, Slovakia, and Bulgaria), Japan, and Korea.
RPR 106972, RPR 112808, and RPR 106950 were obtained from Rhône-Poulenc Rorer, Paris, France; cefditoren was obtained from Meiji Seika Pharma International, Tokyo, Japan; and the two oxazolidinones were obtained from The Upjohn Co., Kalamazoo, Mich. Other compounds were obtained from their respective manufacturers.
MICs were determined by agar dilution on Mueller-Hinton agar supplemented with 5% sheep blood as reported previously (21, (24) (25) (26) . Plates were incubated overnight in ambient air at 37ЊC. All strains grew well without added CO 2 . Standard quality control strains (17) were included in each run. The antimicrobial agent dilutions tested are listed in Table 1 .
The results of susceptibility testing are presented in Table 1 . All penicillin susceptibility groups were inhibited by RPR 106972 at Յ0.5 g/ml. By contrast, the two constituent components of this compound were less active. The MICs at which 50% of the isolates are inhibited (MIC 50 s) and MIC 90 s of RPR 106972 were very similar (0.125 and 0.25 to 0.5 g/ml for erythromycin-susceptible and -resistant strains, respectively). By contrast, RPR 112808 and RPR 106950 were less active against erythromycin-resistant strains.
Cefditoren was very active against all pneumococcal groups, with MICs of Յ2.0 g/ml. Amoxicillin and amoxicillin-clavulanate were the next most active ␤-lactams, followed by cefdinir, cefuroxime, cefpodoxime, and cefprozil. Cefaclor and cefixime were less active, especially against penicillin-intermediate and -resistant strains. The two oxazolidinones were very active against all classes of pneumococci, with MIC 90 s of 0.5 (U-100592) and 1.0 (U-100766) g/ml, respectively, with no differences on the basis of penicillin or erythromycin susceptibility.
MIC 90 s of erythromycin for susceptible, intermediate, and resistant strains were 0.25, Ն128.0, and Ն128.0 g/ml, respectively. Quinolone MICs were not significantly influenced by penicillin susceptibility; sparfloxacin was more active than ciprofloxacin (MIC 90 s, 0.125 and 4.0 g/ml, respectively).
Teicoplanin was more active than vancomycin against all strains, with modal MICs of 0.06 and 0.25 g/ml, respectively. Ceftriaxone and imipenem MICs rose with those of penicillin, but all strains were inhibited by 4.0 and 0.5 g/ml, respectively. With the exception of 19 strains (all from South Africa), all strains were inhibited by rifampin at MICs of Յ2.0 g/ml.
The results of this study indicate that RPR 106972, an oral streptogramin, is as active as RP 59500, its parenteral counterpart, against penicillin-and erythromycin-susceptible and -resistant pneumococcal strains. The higher MICs of RPR 112808 and RPR 106950 for penicillin-intermediate and -resistant strains reflect increased resistance of these strains to erythromycin. RPR 106972 is also active in vitro against staphylococci, beta-hemolytic streptococci, enterococci, Neisseria spp., Haemophilus influenzae, Moraxella catarrhalis, and Legionella spp. (3) .
Cefditoren (ME1207) is a new oral cephalosporin with improved activity against staphylococci, streptococci, H. influenzae, Neisseria gonorrhoeae, and some members of the family Enterobacteriaceae and gram-negative nonfermenters (16) . The MICs of cefditoren for penicillin-susceptible and -resistant pneumococci in our study are similar to those previously reported from France and Spain (7, 9). Preliminary time-kill studies have also documented the superior antipneumococcal activity of cefditoren compared with that of other oral ␤-lactams (7). Additionally, cefditoren seems to possess a capability to select for penicillin-resistant pneumococci in vitro which is similar to or slightly less than that of cefotaxime (18) . The superior activities of amoxicillin and amoxicillin-clavulanate and comparative activities of the other six oral cephalosporins tested have been described previously (2, 10, 14, 15, 19, 21, 25, 26) .
The two oxazolidinones showed very strong antipneumococcal activities, irrespective of the penicillin and erythromycin susceptibility status of strains. The oxazolidinones are oral and parenteral compounds which are active (MIC 90 s, Յ4.0 g/ml) against methicillin-susceptible and -resistant Staphylococcus aureus, Staphylococcus epidermidis, vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium, and penicillin-susceptible and -resistant pneumococci (6, 23) . Administration of a single oral dose of U-100592 to humans resulted in maximum concentrations of drug in serum ranging from 0.16 g/ml at 50 mg to 5.73 g/ml at 1,000 mg. The time to maximum concentration of drug in serum was 0.67 to 2 h (22). The MICs of ceftriaxone and imipenem are similar to those described previously (27) . The superior antipneumococcal activity of sparfloxacin compared with that of ciprofloxacin has been described previously (24, 26) . The superior activity of teicoplanin compared with that of vancomycin is similar to that reported by Goldstein and coworkers (12) . In summary, RPR 106972, cefditoren, U-100592, U-100766, and teicoplanin were very active against penicillin-susceptible and -resistant pneumococci. Clinical studies will be necessary to support these in vitro findings.
